RNU7-115P

Across TCGA pan-cancer cohorts, RNU7-115P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RNU7-115P data layer compared with 14 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher RNU7-115P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU7-115P expression acts as an unfavorable survival marker.

PRAD are the cancer types where RNU7-115P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.072	0.935	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RNU7-115P–PRAD (DFS)

Open the PRAD breakdown →